The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Extended duration of anti-PD-1 therapy, using reduced frequency dosing, in patients with advanced melanoma and Merkel cell carcinoma.
 
Lisa May Ling Tachiki
No Relationships to Disclose
 
Karly Williams Silva
No Relationships to Disclose
 
Daniel S Hippe
Research Funding - Canon Medical System (Inst); GE Healthcare (Inst); Philips Healthcare (Inst)
 
Dane Fritzsche
No Relationships to Disclose
 
Aleksandra Raczka
No Relationships to Disclose
 
Andrea Perdue
No Relationships to Disclose
 
Julia Majovski
No Relationships to Disclose
 
Alexandra Spallone
No Relationships to Disclose
 
Daniel A Goldstein
Stock and Other Ownership Interests - TailorMed; Vivio Health
Consulting or Advisory Role - Vivio Health
Research Funding - BMS (Inst); Janssen (Inst); MSD (Inst)
 
Paul Nghiem
Leadership - Society for Investigative Dermatology (SID)
Honoraria - UpToDate; UpToDate
Consulting or Advisory Role - 4SC; EMD Serono; Merck Sharp & Dohme; Pfizer; Pfizer/EMD Serono; Sanofi/Regeneron
Research Funding - Bristol-Myers Squibb; EMD Serono
Patents, Royalties, Other Intellectual Property - Patent filed: "Merkel cell polyomavirus T antigen-specific TCRs and uses thereof" (Inst); Patent pending for high affinity T cell receptors that target the Merkel polyomavirus.
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Sanofi/Regeneron
 
John A. Thompson
Consulting or Advisory Role - Academy for Continued Healthcare Learning; Alpine Immune Sciences; AVEO; BJ Bioscience; Bristol-Myers Squibb; Calithera Biosciences; Clinical Care Options/NCCN; Meeting Sites Pro; Neoleukin Therapeutics; Regeneron
Research Funding - Agensys (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); PMV Pharma (Inst); Roche (Inst); Trillium Therapeutics (Inst); Xencor (Inst); Xencor (Inst)
 
Evan Thomas Hall
Research Funding - ImCheck therapeutics (Inst); Nektar (Inst); Neoleukin Therapeutics (Inst); Treatment Technologies and Insights (Inst)
Travel, Accommodations, Expenses - Novartis
Other Relationship - Cancer Support Community
 
Shailender Bhatia
Stock and Other Ownership Interests - Moderna Therapeutics
Honoraria - Bristol-Myers Squibb; EMD Serono; EMD Serono; Genentech/Roche; Sanofi/Regeneron; Sanofi/Regeneron
Consulting or Advisory Role - Bristol Myers Squibb; Bristol-Myers Squibb; EMD Serono; EMD Serono; Exicure; Genentech/Roche; Sanofi/Regeneron; Sanofi/Regeneron; Sanofi/Regeneron (Inst)
Research Funding - 4SC (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); EMD Serono (Inst); Exicure (Inst); Immune Design (Inst); Incyte (Inst); Merck (Inst); NantWorks (Inst); Nektar (Inst); Novartis (Inst); OncoSec (Inst); Seven and Eight Biopharmaceuticals (Inst)
Travel, Accommodations, Expenses - NantWorks; Sanofi/Regeneron